Pharma Export: Drawback + RoDTEP + Advance Authorisation Stacking

A Tier-1 integrated pharma formulation exporter running the Ahmedabad plant network closes Q2 FY 2026-27 export books against an illustrative 3,200 shipments to 45 destination markets, aggregating an FOB value of the order of Rs 1,850 crore across the quarter. Every one of those shipments is eligible for at least one — and typically two — of the three DGFT export-incentive schemes that govern the pharmaceutical export cycle. Duty Drawback under the All Industry Rate schedule notified by CBIC covers the embedded customs and central excise duties on imported and indigenous inputs. RoDTEP — the Remission of Duties and Taxes on Exported Products scheme under DGFT Notification 19/2015-20 dated 17 August 2021 with Appendix 4R — covers the embedded central, state and local duties and taxes not otherwise refunded. The Advance Authorisation Scheme under Chapter 4 of the Foreign Trade Policy 2023 permits duty-free import of inputs physically incorporated in the export product, against an export obligation to be discharged within the authorisation validity period. The three schemes stack in a specific compatible-and-exclusive combination at the shipping-bill level. Getting the stacking rule wrong — most commonly by claiming Drawback on a shipping bill where the finished product is manufactured from Advance Authorisation duty-free imported inputs — triggers Customs recovery under Section 74 or 75 of the Customs Act 1962 with interest and, in willful cases, penalty. This is pharma export drawback RoDTEP Advance Authorisation stacking India at operating scale, and the reconciliation discipline that keeps a Tier-1 exporter clean is a per-shipping-bill ledger that links each shipment to its input source, its incentive claim, its e-BRC realisation and — for Advance Authorisation shipments — its authorisation-level annual EODC reconciliation.

The reconciliation in one paragraph

A pharma formulation exporter with a monthly export book of the order of 1,000 to 1,500 shipping bills claims three parallel DGFT export incentives at the shipping-bill level. Duty Drawback under the AIR schedule is credited by the Customs EDI system automatically on filing the shipping bill against the operative HSN Chapter 30 rate — typically 1.5 to 2.5 percent of FOB per the latest DGFT Public Notice. RoDTEP under Appendix 4R is claimed simultaneously and issued as a transferable electronic scrip on the ICEGATE portal after e-BRC realisation is confirmed by the AD bank — typically 1.2 to 1.8 percent of FOB per the latest Appendix 4R revision. Advance Authorisation under Chapter 4 of the Foreign Trade Policy 2023 is exclusive to the input quantum imported duty-free under the authorisation; where a shipping bill’s finished product is manufactured from Advance Authorisation inputs the shipping bill must carry a non-availment declaration for Drawback, and the shipment is instead tagged against the authorisation for annual EODC purposes. The reconciliation surface is per-shipping-bill: incentive amount claimed, incentive amount credited, e-BRC realisation status, RoDTEP scrip issuance status and (for Advance Authorisation shipments) the running authorisation ledger of SION-entitled duty-free imports against actual export performance. At authorisation close, the annual EODC filing reconciles the SION-mapped position with the actual position and any Export Obligation Lapse triggers customs duty recovery plus interest on the un-utilised import quantum.

What the scenario looks like in India — safe illustrative brand persona

The Indian pharma export cycle runs across a small number of Tier-1 integrated formulation exporters that account for the bulk of national Chapter 30 outbound value, and a broader set of Tier-2 specialty exporters that anchor specific therapy areas or regional distributor relationships. The Tier-1 palette includes Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Cipla, Aurobindo Pharma, Lupin, Zydus Lifesciences (the merged entity formerly Cadila Healthcare), Torrent Pharmaceuticals, Alkem Laboratories, Glenmark Pharmaceuticals and Cadila Pharmaceuticals — each running multi-plant formulation footprints with a mix of regulated market exports (US, EU, Japan, Canada, Australia) and semi-regulated and emerging market exports (Sub-Saharan Africa, LatAm, CIS, Southeast Asia). The Tier-2 palette includes Biocon Biologics, Divi’s Laboratories (skewed to Chapter 29 API export), Piramal Pharma, Ipca Laboratories, Ajanta Pharma, Natco Pharma, Laurus Labs, Granules India, Strides Pharma Science, JB Chemicals & Pharmaceuticals and Wockhardt.

For the reconciliation this article walks through, the reference persona is a Tier-1 integrated formulator whose Ahmedabad plant network — comprising formulation lines at the Ahmedabad, Vadodara and Halol clusters — files an aggregate Q2 FY 2026-27 export book of the order of 3,200 shipping bills to 45 destination markets at approximately Rs 1,850 crore aggregate FOB value. The destination mix runs from regulated market shipments (US ANDA-authorised shipments to distributor DCs, EU CEP-certified shipments to marketing authorisation holders, Japan PMDA-registered shipments) through emerging market shipments (Sub-Saharan Africa WHO PQ shipments, Nigeria NAFDAC-registered shipments, South Africa SAHPRA-registered shipments to the Cipla Medpro distribution parallel, LatAm ANVISA and COFEPRIS shipments, Brazil and Mexico bulk shipments) to CIS and Southeast Asia semi-regulated shipments. Each shipping bill carries an INCOTERM 2020 code — FCA on the majority of EU shipments (favouring risk transfer at the Indian port), FOB or CFR on the majority of emerging market shipments, DDP on selected regulated market shipments where the exporter absorbs destination duty. Payment terms range from sight-LC on emerging market shipments (typical 30 to 90 day realisation cycle) to open account on regulated market distributor shipments (typical 90 to 180 day realisation cycle).

The regulatory overlay — three DGFT schemes and one Customs recovery mechanic

Duty Drawback under the Customs Drawback Rules 2017 read with Section 75 of the Customs Act 1962 is the oldest of the three schemes and refunds the customs and central excise duties suffered on imported and indigenous inputs used in the manufacture of exported goods. The All Industry Rate (AIR) drawback schedule is notified by CBIC through a periodic DGFT Public Notice, with product-specific rates against Chapter Heads of the Customs Tariff. Pharmaceutical formulations under HSN Chapter 30 typically carry AIR drawback in the range of 1.5 to 2.5 percent of FOB value; the operative rate for each 8-digit HSN sub-heading must be verified against the latest DGFT Public Notice. Section 74 covers drawback on re-export of imported goods (a smaller footprint for a Chapter 30 formulator); Section 75 covers the operative mechanism for the exporter’s manufactured-goods drawback claim.

RoDTEP — Remission of Duties and Taxes on Exported Products — under DGFT Notification 19/2015-20 dated 17 August 2021 was introduced to remit embedded central, state and local duties and taxes on exported products that are not otherwise refunded through Duty Drawback, GST refund under Rule 89(5) for inverted duty structure or any other mechanism. The scheme operates through a transferable electronic scrip credited to the exporter’s ledger on the ICEGATE portal after the export proceeds are realised in freely convertible foreign exchange. Appendix 4R notifies the RoDTEP rate per 8-digit HSN; pharmaceutical formulations under Chapter 30 typically carry a RoDTEP rate in the range of 1.2 to 1.8 percent of FOB. RoDTEP is compatible with Duty Drawback on the same shipping bill — an exporter claims both simultaneously against the same shipment. RoDTEP’s compatibility with Advance Authorisation shipments has been the subject of successive DGFT notifications since the scheme’s introduction; the current position must be verified against the latest DGFT Public Notice at filing time.

Advance Authorisation Scheme under Chapter 4 of the Foreign Trade Policy 2023 permits an exporter to import inputs duty-free, subject to the inputs being physically incorporated in the export product, a positive value addition and the actual user condition. The scheme operates against Standard Input-Output Norms (SION) notified by the Norms Committee for finished product HSN and descriptions; where no SION exists, the exporter files for an ad-hoc norm under the Handbook of Procedures Chapter 4. The authorisation carries an export obligation to be discharged within the validity period. The exclusive-stacking rule is that duty-free imports under Advance Authorisation extinguish the entitlement to Duty Drawback on the same input quantum — the underlying customs duty was never suffered because it was exempted at import, so it cannot be refunded on export. The shipping bill for a finished product manufactured from Advance Authorisation inputs must declare non-availment of Drawback in the specified declaration field. At authorisation validity end, the exporter files the annual Export Obligation Discharge Certificate (EODC) with DGFT — the EODC reconciles the SION-entitled input quantum against the actual export performance and any Export Obligation Lapse triggers recovery of the customs duty foregone plus interest at the notified rate (typically 15 percent per annum) from the date of import.

A worked example — the Ahmedabad plant Q2 FY 2026-27 export book

Illustrative — the following figures represent the operating pattern of a Tier-1 pharma formulation exporter running a multi-plant Ahmedabad cluster export book. Public disclosures do not reveal per-shipping-bill export-incentive quantum in the granularity below; cross-verify against your own shipping bill register and ICEGATE scrip ledger before action.

The Ahmedabad plant network closes Q2 FY 2026-27 with the following aggregate export incentive position:

Of the 3,200 shipments in Q2, 850 shipments (worth approximately Rs 520 crore in FOB) are manufactured from inputs imported duty-free under one of the exporter’s live Advance Authorisations. These 850 shipments carry the non-availment declaration in the shipping bill; the exporter’s own shipping-bill-to-authorisation linkage register maps each of the 850 shipments to the specific authorisation number. The remaining 2,350 shipments (worth approximately Rs 1,330 crore) are eligible for stacked Duty Drawback plus RoDTEP; the aggregate drawback claim is approximately Rs 26.6 crore (at an assumed 2.0 percent average AIR rate on the eligible base) and the aggregate RoDTEP claim is approximately Rs 20.0 crore (at an assumed 1.5 percent average Appendix 4R rate). The combined incentive on the Drawback-plus-RoDTEP leg is approximately Rs 46.6 crore for the quarter, or about 3.5 percent of the eligible-base FOB value.

The e-BRC realisation ageing is the primary treasury control. Of the 3,200 shipments 1,850 realise within 90 days, 1,120 realise between 90 and 180 days, and 230 remain outstanding beyond 180 days at quarter-end. The 230 outstanding shipments are the FEMA regulatory watch surface — under the RBI Master Direction on Export of Goods and Services, outstanding realisation beyond nine months from the shipping date requires either extension of time from the AD bank or write-off with RBI approval. From the RoDTEP perspective, the scrip issuance on ICEGATE is gated on e-BRC realisation; the 230 pending shipments carry an approximately Rs 2.1 crore RoDTEP entitlement (Rs 140 crore at 1.5 percent) that will only credit as scrip on realisation.

For the Advance Authorisation leg, the exporter runs an aggregate 12 live authorisations spanning finished product HSN codes across the therapeutic portfolio. The Q2 SION-mapped duty foregone of approximately Rs 68 crore represents the customs duty that would have been payable at the notional 8 to 10 percent effective rate on the duty-free API and intermediate imports made under those 12 authorisations. Each authorisation runs its own annual EODC clock; the reconciliation obligation is to close each authorisation on time with the SION-mapped export performance reconciled against the actual duty-free import quantum. Any Export Obligation Lapse at closure triggers customs duty recovery plus interest at the notified rate (typically 15 percent per annum) from the date of import.

Common reconciliation breakages

Five breakages recur across Indian Chapter 30 formulation exporters running the stacked Drawback-plus-RoDTEP-plus-Advance-Authorisation cycle, and each maps to a specific control failure that surfaces either at Customs post-audit or at DGFT annual EODC scrutiny.

• Missing Advance Authorisation non-availment declaration on the shipping bill. The highest-severity failure mode. A shipping bill for a finished product manufactured from Advance Authorisation duty-free imported inputs that does not carry the non-availment declaration triggers automatic drawback credit in the Customs EDI system on the AIR schedule. The mis-credited drawback is subsequently recovered under Section 74 or Section 75 of the Customs Act 1962 with interest and, in willful cases, penalty. The failure sits in the exporter’s own shipping-bill-to-authorisation linkage discipline — the Customs system does not automatically surface the linkage. See the reconciliation error catalogue for the human-error taxonomy that classifies this class of mis-declaration.

• Stale HSN rate register at shipping bill filing. Drawback rates under the AIR schedule and RoDTEP rates under Appendix 4R are revised periodically through DGFT Public Notices. An exporter running against a stale HSN rate register at the shipping bill filing timestamp claims the wrong incentive amount — either over-claiming (recovered at audit) or under-claiming (irrecoverable at post-audit stage under the shipping-bill-date rate freeze). Reconciliation discipline: the HSN rate register is refreshed against each DGFT Public Notice with an effective-date audit trail.

• e-BRC realisation lag not tracked against RoDTEP scrip issuance. RoDTEP scrip only issues on ICEGATE after e-BRC realisation confirmation from the AD bank. Exporters that treat the RoDTEP claim as booked income at shipping bill filing without tracking the realisation-to-scrip-issuance ageing carry an incentive receivable on the balance sheet that has not yet crystallised as scrip credit. On the FEMA side, realisation beyond nine months requires AD bank extension of time or RBI write-off approval; on the RoDTEP side, unrealised shipments do not credit scrip at all.

• SION-mapped export quantum tracked at aggregate rather than per-authorisation level. An exporter with 12 live Advance Authorisations that tracks the SION-mapped export performance at aggregate level rather than per-authorisation level cannot generate the annual EODC filing accurately — the EODC is filed per authorisation and requires the specific authorisation’s SION-entitled input quantum reconciled with the actual exports performed under that authorisation. Aggregate tracking produces a mis-attribution of exports across authorisations and either an over-claim of export obligation discharge or an unnecessary Export Obligation Lapse recovery.

• Ind AS 21 forex-translation mis-match with RoDTEP scrip rupee value. The export receivable under Ind AS 21 is initially recognised at the invoice-date spot rate, translated at the closing balance sheet rate, and settled at the realisation-date rate — with the forex variance flowing to the P&L. The RoDTEP scrip is denominated in rupees and issued at the shipping-bill-date FOB rupee equivalent. Exporters that do not reconcile the two rupee bases produce a P&L export incentive income line that does not tie cleanly to the shipping bill FOB base. See the reconciliation playbook for monthly close for the monthly ledger-tie-out discipline that catches this class of mis-match.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the shipping bill register from the exporter’s own ERP or from the ICEGATE download, the Customs EDI drawback credit register, the ICEGATE RoDTEP scrip ledger, the e-BRC status extract from the AD bank and the Advance Authorisation master with SION mapping — and produces a per-shipping-bill export incentive close pack that reconciles the claimed-versus-credited drawback and RoDTEP amounts, flags the Advance Authorisation non-availment declaration status on every shipment linked to a live authorisation, ages the e-BRC realisation against the RoDTEP scrip issuance, and generates the annual EODC reconciliation report at authorisation close date. Match rate improvement of 51 to 88 percent on the shipping bill to Customs EDI credit reconciliation, together with an ISO 27001:2022 information security posture and DPDP Act 2023 aligned data handling on the AD bank e-BRC feed, is what makes the platform an infrastructure investment for a Tier-1 pharma exporter running a monthly 1,000 to 1,500 shipping bill book rather than a spreadsheet substitute. Cross-cluster methodology anchors sit in the reconciliation failure mode analysis pillar and in the human errors and detection envelope anchor. The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority is reconciliation software India.

The five FAQs below address the operational questions Indian pharma exporters and their indirect-tax leads ask most often when building a standing per-shipping-bill export incentive close that stacks Drawback, RoDTEP and Advance Authorisation with the discipline that keeps the Customs post-audit and the DGFT annual EODC scrutiny clean.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 17 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024